Exploring Intratumoral Immunotherapy in Melanoma and Other Malignancies

February 8, 2020
Jason Luke, MD, FACP

Jason Luke, MD, FACP, discusses promising clinical research around intratumoral immunotherapy.

Jason Luke, MD, FACP, associate professor of medicine in the Division of Hematology/Oncology and the director of the Cancer Immunotherapeutic Center at the UPMC Hillman Cancer Center, discusses promising clinical research around intratumoral immunotherapy.

There are multiple studies in the area of intratumoral immunotherapy that have the potential to make a large impact in the field, says Luke. One notable trail is a randomized phase III, which is evaluating tilsotolimod with or against ipilimumab (Yervoy) in patients with melanoma. If the trial is positive, it may impact the standard of car, by offering a new option for patients with melanoma who progress on a PD-1 inhibitor.